Chengdu Shengnuo Technology Development Co., Ltd., a group company of Chengdu Capgemini Biomedical Development Co., Ltd., was formally established on 200 1. Its core personnel, that is, the managers of various departments of the later group, are the backbone of large-scale biopharmaceutical enterprises in China and the first batch of R&D personnel engaged in R&D and chemical production of peptide pharmaceutical industry in China.
In the same year, the inherent polypeptide synthesis technology was organically integrated with the successfully developed products in China, which made perfect preparations for future laboratory construction and new project research and development.
In 2002, the small laboratory of Chengdu Shengnuo Technology Development Co., Ltd. was successfully transformed and the first batch of R&D equipment was purchased. In September, 2002, some R&D personnel of the company had a technical exchange with the Department of Chemistry of the University of Southern California, USA, and introduced the international advanced peptide synthesis method and R&D perspective into China, which made clear the development focus of the company's R&D strength first.
Chengdu Capgemini Biomedical Development Co., Ltd. was established in 2003, focusing on the research and development of polypeptide products and the customized synthesis of customer peptides. Three laboratories were added, and the number of experimenters increased to 12. At the end of the year, the company introduced the second batch of equipment, including CSBio automatic polypeptide synthesizer and multi-flux synthesizer imported from the United States, to adapt to the expanding customized synthesis business.
In 2004, Chengdu Shengnuo Biopharmaceutical Co., Ltd., a subsidiary of the group, was established, focusing on the production of polypeptide raw materials. The company's raw materials such as thymosin, thymopentin and somatostatin have formed a complete and advanced technological process, which enjoys a high reputation in the domestic polypeptide field!
In 2005, the group invested 70 million yuan to buy a factory with a total area of 10 hectares in Dayi Industrial Park to build a new factory building. At the same time, we will carry out all-round integrated marketing, participate in international polypeptide industry conferences and API exhibitions, and promote Capgemini brand to all parts of the world.
Chengdu Jinuo Chemical Co., Ltd. was established, mainly engaged in the production projects of protecting amino acids, resins and chemical raw materials. The group continues to introduce undergraduate and graduate students from universities as training forces.
In 2006, the group completed the construction of a new factory and passed the acceptance test in the same year, and moved to Dayi Industrial Park. The new factory is divided into three planning areas. The production area has100000 peptide synthesis workshop, customized peptide synthesis workshop, API workshop and preparation production workshop.
In 2007, the group began to prepare for the approval of related drugs. At the beginning of the year, Capgemini absorbed a doctor of production management from a large pharmaceutical company in California and a chemist from the Biology Department of Cambridge University in England, and adopted an optimized management system and production process to push Chengdu Capgemini to a new height. In the same year, Chengdu Shengnuo Technology became one of the fastest growing enterprises in Sichuan Province.
In 2008, Chengdu Capgemini Biomedical Technology Development Co., Ltd. became a long-term raw material supplier for two local pharmaceutical companies in the United States/KLOC-0. And signed supply cooperation agreements with importers in Europe and India. During this year, he participated in CPHI in Brazil, CPHI in Europe and sponsored the American Polypeptide Conference, all of which achieved ideal results.
In the same year, thymopentin API obtained GMP certification.
Chengdu Capgemini Import and Export Trading Co., Ltd. was established in 2009, and the establishment of this subsidiary has better adapted to the international development requirements of the group's business. In the same year, Shengnuo Bio-pharmaceutical Co., Ltd. obtained a new GMP certification certificate for an API and a preparation, and the company will continue to declare more than 20 products in the same period.
At that time, it became one of the largest import manufacturers of polypeptide raw materials in India. The FDA production workshop of the company started construction, and it is expected to be completed in 20 1 1, and it has been certified by FDA of the United States and s FDA of China.